CompletedNCT07628153
Mindfulness and Biofeedback for Anxiety Disorders
Medication studyAges 19–74Russia
Understand this study
Who was this study for?
This study was for people with anxiety. Listed age limits: 19 years to 74 years. Other eligibility criteria applied.
- Listed locations
- MoscowSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: July 11, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 188
- Sponsor
- I.M. Sechenov First Moscow State Medical University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Combination product, Device, Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Russia
- Age range
- From 19 Years to 74 Years
- Official registry ID
- NCT07628153
- Official title
Show the full official title
Development of Mindfulness Through Adaptive Biofeedback Methods in the Treatment of Anxiety Disorders: Randomized Controlled Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Moscow, Russia · Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is I.M. Sechenov First Moscow State Medical University, a university.
Did this study involve medication?
Yes. The study involved medication, including Escitalopram 10 mg/day.
Who was this study for?
This study was for people with anxiety. Listed age limits: 19 years to 74 years. Other eligibility criteria applied.
